stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Return on invested capital
AxoGen, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −5.27%, down 2.0 percentage points from fiscal 2025 (−3.25%). Over the past ten years it has ranged from −82.9% (fiscal 2015) to −1.54% (fiscal 2024); the current reading is higher than 91% of that period. That is in line with the Medical Devices industry median of −5.27% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −3.25% | (1.71) |
| FY2024 | −1.54% | 9.07 |
| FY2023 | −10.6% | 5.76 |
| FY2022 | −16.4% | 1.35 |
| FY2021 | −17.7% | 4.20 |
| FY2020 | −21.9% | 37.61 |
| FY2019 | −59.5% | (7.23) |
| FY2018 | −52.3% | (15.00) |
| FY2017 | −37.3% | 17.82 |
| FY2016 | −55.1% | 27.76 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| TMDX TransMedics Group, Inc. compare | 48.0% |
| UFPT UFP Technologies, Inc. compare | 11.2% |
| ITGR Integer Holdings Corporation compare | 3.16% |
| INSP Inspire Medical Systems, Inc. compare | 1.97% |
| NEOG Neogen Corporation compare | −0.17% |
| AXGN AxoGen, Inc. | −5.27% |
| ESTA Establishment Labs Holdings Inc. compare | −5.53% |
| ALMR Alamar Biosciences, Inc. compare | −10.1% |
| IRTC iRhythm Holdings, Inc. compare | −11.4% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement